Ocular Therap

OCUL

6.8201.34% ( +0.090 )

Closed: Nov 3, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is -4.97, above the reasonable range, cheaper than 19.03% of the time in the past 5 years, and the industry ranks 171/257, the industry Median -1.10.

-4.97xP/E

Stock price$6.82Earnings per share$-1.37

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

03774111148

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
BAYRYUSBayer	-28.11x	--	$56.63B
BAYZFUSBayer Aktiengesellschaft	-28.58x	--	$57.57B
VTRSUSViatris	-52.91x	107.68%	$21.73B
ELANUSElanco Animal Health	-61.69x	130.52%	$12.28B
CURLFUSCuraleaf Holdings, Inc.	-149.19x	--	$7.76B
ABVXUSAbivax SA	-16.63x	22.99%	$7.73B
AXSMUSAxsome Therap	-46.49x	31.04%	$7.31B
VREOFUSVIREO GROWTH INC	-105.44x	--	$7.08B
BLTEUSBelite Bio	-59.87x	29.87%	$6.13B
MANEUSVeraDermics	-53.53x	97.44%	$5.58B
DFTXUSDefinium Therapeutics	-12.69x	54.55%	$4.49B
EWTXUSEdgewise Therapeutics	-20.75x	187.50%	$4.09B
AMLXUSAmylyx Pharmaceuticals	-24.10x	1.76%	$3.66B
ELVNUSEnliven Therapeutics	-31.01x	5.59%	$3.28B
TARSUSTarsus Pharmaceuticals	-68.59x	345.28%	$3.19B
RGCUSRegencell Bioscience	-260.40x	--	$3.05B
BHCUSBausch Health	-3.62x	511.90%	$3.04B
MBXUSMBX Biosciences	-25.40x	31.12%	$2.65B
PHVSUSPharvaris BV	-12.32x	10.43%	$2.44B
TRLVUSTrulieve Cannabis	-4.70x	198.82%	$2.22B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.